Similar cases include the dominant role of CD43 in leukemia cell line K562[15] and of CD24 in ovarian and breast cancer cells.[47] The workflow presented in this work combined the strengths of proximity labeling and genetic screening and could provide a general approach to identify cancer cell‐specific counter receptors of Siglecs. The gene discussed is CD24; the disease is breast carcinoma.